DK3154957T3 - Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser - Google Patents

Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser Download PDF

Info

Publication number
DK3154957T3
DK3154957T3 DK15714185.4T DK15714185T DK3154957T3 DK 3154957 T3 DK3154957 T3 DK 3154957T3 DK 15714185 T DK15714185 T DK 15714185T DK 3154957 T3 DK3154957 T3 DK 3154957T3
Authority
DK
Denmark
Prior art keywords
methyl
histonmethyl
honorable
transfer
transferases
Prior art date
Application number
DK15714185.4T
Other languages
Danish (da)
English (en)
Inventor
Ena Xabier Aguirre
Santamarina Julen Oyarzabal
Cardoso Felipe Prósper
Gracia Maria Obdulia Rabal
Madoz Juan Roberto Rodríguez
José Enériz Edurne San
Original Assignee
Fundacion Para La Investig Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Para La Investig Medica Aplicada filed Critical Fundacion Para La Investig Medica Aplicada
Application granted granted Critical
Publication of DK3154957T3 publication Critical patent/DK3154957T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK15714185.4T 2014-06-16 2015-03-30 Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser DK3154957T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382230 2014-06-16
PCT/EP2015/056860 WO2015192981A1 (en) 2014-06-16 2015-03-30 Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases

Publications (1)

Publication Number Publication Date
DK3154957T3 true DK3154957T3 (da) 2020-02-17

Family

ID=51136403

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15714185.4T DK3154957T3 (da) 2014-06-16 2015-03-30 Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser

Country Status (9)

Country Link
US (1) US9840500B2 (enExample)
EP (1) EP3154957B1 (enExample)
JP (1) JP6527534B2 (enExample)
CN (1) CN106536509B (enExample)
AU (1) AU2015276537B2 (enExample)
CA (1) CA2987978C (enExample)
DK (1) DK3154957T3 (enExample)
ES (1) ES2769648T3 (enExample)
WO (1) WO2015192981A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127354A1 (en) * 2015-12-14 2019-05-02 Fundación Para La Investigación Médica Aplicada 2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases
IL307931A (en) * 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2017201199A1 (en) * 2016-05-17 2017-11-23 Duke University Compositions and methods for the treatment of prader-willi syndrome
WO2018049000A1 (en) * 2016-09-08 2018-03-15 The General Hospital Corporation Treatment of cancers having alterations within the swi/snf chromatin remodeling complex
US11103549B2 (en) 2016-12-22 2021-08-31 Asddr, Llc Use of histone methyltransferase inhibitors and histone deacetylase inhibitors for therapy of Phelan-McDermid Syndrome
EP4063358B1 (en) * 2016-12-22 2024-05-22 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
MX2019014759A (es) 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
MX2020001825A (es) 2017-08-15 2020-03-20 Global Blood Therapeutics Inc Compuestos triciclicos como inhibidores de metiltransferasa de histona.
US11584734B2 (en) 2017-08-15 2023-02-21 Global Blood Therapeutics, Inc. Tricyclic compounds as histone methyltransferase inhibitors
MX2020007152A (es) * 2017-10-18 2020-12-10 Epizyme Inc Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
AU2018353150B2 (en) * 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
WO2019229765A1 (en) * 2018-05-29 2019-12-05 Council Of Scientific & Industrial Research, India Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
WO2019243236A1 (en) 2018-06-18 2019-12-26 Fundación Para La Investigación Médica Aplicada New anticancer drug combinations
CN112390791B (zh) * 2019-08-14 2023-08-01 复旦大学 一类dna甲基转移酶1荧光探针及其用途
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
EP4192826A4 (en) * 2020-08-07 2024-09-04 Athos Therapeutics, Inc. SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN115160294B (zh) * 2022-06-27 2023-09-29 中山大学 一种G9a/GLP共价抑制剂及其制备方法及应用
CN120965666B (zh) * 2025-10-21 2026-02-17 四川大学华西医院 一种喹啉类化合物、制备方法和用途及其药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE408422T1 (de) 1997-07-03 2008-10-15 Donald E Macfarlane Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
CA2412345A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
EP1088818B1 (en) 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003297460A1 (en) 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
ES2389258T3 (es) * 2003-06-17 2012-10-24 Millennium Pharmaceuticals, Inc. Composiciones y métodos para inhibir TGF-s
EP2078008A2 (en) 2006-10-12 2009-07-15 SuperGen, Inc. Quinoline derivatives for modulating dna methylation
CN101535295A (zh) * 2006-10-12 2009-09-16 休普基因公司 用于调节dna甲基化的喹啉衍生物
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
CN102625799A (zh) * 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
EP2464723B1 (en) * 2009-08-12 2016-06-22 Kyoto University Method for inducing differentiation of pluripotent stem cells into neural precursor cells
WO2011054433A1 (en) * 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
US20140357594A1 (en) 2011-10-24 2014-12-04 Glaxosmithkline Intellectual Property (No.2) Limited New compounds
ES2872348T3 (es) * 2012-03-19 2021-11-02 Imperial College Innovations Ltd Compuestos de quinazolina y su uso en terapia
EP2730558A1 (en) 2012-11-08 2014-05-14 Ikerchem, S.L. Indole derivatives, pharmaceutical compositions containing such indoles and their use as DNA methylation modulators
US9264060B2 (en) * 2012-11-09 2016-02-16 St-Ericsson Sa Analog to digital conversion method with offset tracking and correction and analog to digital converter implementing the same
ES2635016T3 (es) * 2013-03-01 2017-10-02 Fundación Para La Investigación Médica Aplicada Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas

Also Published As

Publication number Publication date
ES2769648T3 (es) 2020-06-26
US9840500B2 (en) 2017-12-12
JP2017524668A (ja) 2017-08-31
EP3154957A1 (en) 2017-04-19
EP3154957B1 (en) 2019-11-20
WO2015192981A1 (en) 2015-12-23
CN106536509A (zh) 2017-03-22
AU2015276537A1 (en) 2017-01-05
JP6527534B2 (ja) 2019-06-05
US20170121316A1 (en) 2017-05-04
CA2987978A1 (en) 2015-12-23
CN106536509B (zh) 2020-06-09
AU2015276537B2 (en) 2019-03-14
CA2987978C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
IL263586B (en) Inhibitors of the menin-mll interaction
DK3119772T3 (da) Heteroaryl syk-hæmmere
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
IL248410A0 (en) A system for the closed transfer of liquids
DK3158054T3 (da) Genetisk modificerede bakterier og fremgangsmåder til genetisk modifikation af bakterier
DK3536685T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser og anvendelse deraf som irak4 inhibitorer
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3207043T6 (da) Dihydropyrrolopyridin-inhibitorer af ror-gamma
LT3303334T (lt) Tirozinkinazės inhibitoriai
HRP20190407T1 (hr) Heteroarilni spojevi za inhibiciju kinaza
DK3183260T3 (da) Modificerede oligonukleotider og fremgangsmåder til deres syntese
DK3718507T3 (da) Anordninger til behandling af nedre ekstremitetsvaskulatur
HRP20181899T1 (hr) Biaril inhibitori kinaze
EP4096138C0 (en) DATA TRANSMISSION METHODS
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3371165T3 (da) Btk-inhibitor til anvendelse til behandling af kræft
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3157929T3 (da) Pyrazolforbindelser som modulatorer af fshr og anvendelser deraf
DK3341379T3 (da) EZH2-hæmmere
DK3481819T3 (da) Forbindelser og anvendelse deraf til reducering af urisyreniveauer
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere